# Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

> **NCT02438995** · PHASE1 · TERMINATED · sponsor: **Northwell Health** · enrollment: 11 (actual)

## Conditions studied

- Carcinoma, Squamous Cell
- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **DRUG:** Intraarterial Cetxuimab (Erbitux)

## Key facts

- **NCT ID:** NCT02438995
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2021-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02438995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02438995, "Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02438995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*